Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-01 00:48:33 - browse：1

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Prior authorization will have to move faster under new Biden rule

WSS

Study on Amgen’s bispecific immunotherapy produces positive data

STAT Summit: Ending the crisis of Black deaths in the U.S.

Why doctors need education on FDA device approval process

Merck, Daiichi strike cancer drug pact worth up to $22 billion

UnitedHealth, Optum discontinue NaviHealth name

Roivant's CEO is a star, but biotech's black hole persists

focus

Wikipedia

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

J&J lung cancer data amount to new salvo against AstraZeneca

Tori Bowie and the unacceptable rates of Black maternal death

Results on Novartis prostate cancer therapy could expand its use

Medical records are filled with copy

STAT Summit: Ending the crisis of Black deaths in the U.S.

Supreme Court strikes down use of affirmative action

Francis Collins on trust in science and how Covid communications failed

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Wikipedia

Health tech investors get more selective as pandemic boom fades

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

STAT Summit: How researchers deal with rejection

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Study on Amgen’s bispecific immunotherapy produces positive data

Health tech investors get more selective as pandemic boom fades

focus

explore

hotspot

hotspot